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Abstract
Aberrant histone deacetylase (HDAC) activity is frequent in human leukemias. However, while classical, NAD
+-independent
HDACsareanestablishedtherapeutictarget,therelevanceofNAD
+-dependentHDACs(sirtuins)inleukemiatreatmentremains
unclear. Here, we assessed the antileukemic activity of sirtuin inhibitors and of the NAD
+-lowering drug FK866, alone and in
combination withtraditional HDAC inhibitors. Primaryleukemiacells, leukemiacelllines,healthy leukocytesand hematopoietic
progenitors were treated with sirtuin inhibitors (sirtinol, cambinol, EX527) and with FK866, with or without addition of the
HDAC inhibitors valproic acid, sodium butyrate, and vorinostat. Celldeath was quantified by propidium iodide cell staining and
subsequentflow-cytometry.Apoptosisinduction wasmonitored bycellstainingwithFITC-Annexin-V/propidiumiodideorwith
TMRE followed by flow-cytometric analysis, and by measuring caspase3/7 activity. Intracellular Bax was detected by flow-
cytometry and western blotting. Cellular NAD
+ levels were measured by enzymatic cycling assays. Bax was overexpressed by
retroviral transduction. Bax and SIRT1 were silenced by RNA-interference. Sirtuin inhibitors and FK866 synergistically enhanced
HDAC inhibitor activity in leukemia cells, but not in healthy leukocytes and hematopoietic progenitors. In leukemia cells, HDAC
inhibitors were found to induce upregulation of Bax, a pro-apoptotic Bcl2 family-memberwhose translocation to mitochondria
is normally prevented by SIRT1. As a result, leukemia cells become sensitized to sirtuin inhibitor-induced apoptosis. In
conclusion, NAD
+-independent HDACs and sirtuins cooperate in leukemia cells to avoid apoptosis. Combining sirtuin with
HDAC inhibitors results in synergistic antileukemic activity that could be therapeutically exploited.
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Introduction
Histone deacetylases (HDACs) regulate the acetylation status of
histones and other intracellular substrates. Four classes of HDACs
have been identified, three of which are NAD
+-independent
HDACs (class I, II, and IV, referred to here as classical HDACs;
and their inhibitors as HDAC inhibitors) [1,2]. The recently
discovered class III HDACs are sirtuins (SIRT1-7) [3]. Mamma-
lian sirtuins are homologs of the yeast silent information regulator
2 (Sir2), and are characterized by a unique NAD
+-dependent
enzymatic activity [4].
Classical HDACs have long been known for their involvement
in cancer, including leukemias [1,2]. Aberrant HDAC activity is
commonly observed in leukemia cells, leading to skewed gene
expression, increased proliferation, and resistance to apoptosis
[1,2]. HDAC inhibitors, some of which have been available for
decades, show antileukemic activity in vitro and in animal models,
and thus underwent clinical evaluations, mostly for acute myelo-
genous leukemia (AML) and myelodysplastic syndromes [5,6,
7,8,9]. Overall, these agents are very well tolerated, which makes
them particularly suited for treating elderly patients or patients
with relevant co-morbidities. However, although the most recent
inhibitors, such as vorinostat and romidepsin, appear to be more
active than traditional valproic acid (VA), HDAC inhibitors alone
will rarely induce disease remissions, their benefit being mostly
limited to hematological improvements [5,6,7,8,9]. Thus, strate-
gies to increase their efficacy are warranted.
Recently, sirtuins, particularly SIRT1, have also been proposed
to play a role in leukemogenesis [10]. SIRT1 was found to be
overexpressed in AML and in B-cell chronic lymphocytic leukemia
PLoS ONE | www.plosone.org 1 July 2011 | Volume 6 | Issue 7 | e22739(B-CLL), and downregulated during neutrophil differentiation of
acute promyelocytic leukemia cells [11,12,13]. It was reported that
SIRT1 antagonizes PML-induced cellular senescense [14].
Moreover, increased SIRT1 levels were detected in chemoresis-
tant leukemia cells and in imatinib-resistant chronic myelogenous
leukemia cells [10,15]. The mechanisms invoked to explain
SIRT1’s oncogenic activity are mostly related to its role in cell
defenses and survival in response to stress. SIRT1 directly dea-
cetylates, and consequently inactivates, p53 [16,17]. Moreover,
SIRT1 prevents apoptosis in response to damage or stress by
interfering with the activity of the FOXO family of transcription
factors, of Bax, Rb, and of E2F1 [10].
Sirtuins are virtually unaffected by all HDAC inhibitors cur-
rently available [18]. However, numerous small-molecule sirtuin
inhibitors have been described, several of which show anticancer
activity in preclinical models [10,19]. Moreover, nicotinamide
phosphoribosyltransferase (Nampt) inhibitors, such as FK866 [20],
by lowering intracellular NAD
+ concentrations, deprive sirtuins of
their substrate and thus reduce their activity [21]. Indeed, in many
instances, pharmacological Nampt inhibition has been shown to
recreate the biological consequences of sirtuin obstruction or
genetic deletion [20,21,22,23,24,25].
In this study, we evaluated sirtuin inhibitors and FK866, either
alone or in combination with HDAC inhibitors, for their anti-
leukemic activity. To this end, we made use of a large cohort of:
primary leukemia cells; leukemia cell lines; healthy leukocytes and
hematopoietic progenitors. Our results indicate that sirtuins and
classical HDACs cooperate in leukemia cells to prevent apoptosis.
Combined inhibition of the two types of HDACs results in a
synergistic antileukemic activity with potential to have clinical
applications.
Results
Sirtuin inhibitors synergistically enhance HDAC inhibitor
activity in human leukemia cells
We investigated the antileukemic activity of the sirtuin inhibitors
sirtinol, cambinol, and EX527. Sirtinol and cambinol are reported
to inhibit SIRT1 and SIRT2 [10]. EX527 selectively inhibits
SIRT1 when used at concentration in the nanomolar or low-
micromolar range, whilst at higher drug concentrations it also
inhibits SIRT2 (IC50, 19.6 mM) and SIRT3 (IC50, 48.7 mM) [26].
Sirtuin inhibitors were either used alone or in combination with
the HDAC inhibitors VA and butyrate (BU). These inhibitors
were tested on a large cohort of primary AML and B-CLL sam-
ples. In addition, for additional titration and follow-up experi-
ments we made use of the leukemia cells lines U937 (AML), 697
(pre-B-cell leukemia), and Jurkat (acute T-cell leukemia). Finally,
healthy peripheral blood mononuclear cells (PBMCs) were also
treated with these drug combinations. Cell viability was assessed
after a 48 h treatment by standard propidium iodide (PI) staining
and flow cytometry. Throughout these experiments, sirtuin inhi-
bitors and HDAC inhibitors were found to have partial cytotoxic
activity in leukemia cells when used as single agents (with specific
cell deaths that were typically ,50%) (Figure 1, S1, S2, S3, and
Tables S1, S2, S3, S4). Co-administration of an HDAC inhibitor
Figure 1. HDAC and sirtuin inhibitors synergistically kill primary AML cells. Primary AML cells were incubated with or without sirtuin
inhibitors (EX527, sirtinol, cambinol) in the presence or absence of VA at the indicated concentrations. Viability was assessed 48 h later by PI cell
staining and flow cytometry. CI values refer to the highest drug concentrations used. CI
CTs for each drug combination are presented in the lower
insets. An effect of 1 corresponds to 100% specific death whereas an effect of 0 corresponds to 0% specific death.
doi:10.1371/journal.pone.0022739.g001
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their cytotoxic activity, as shown by calculation of both coopera-
tive index (CI) and combination index according to Chou and
Talalay statistics (CI
CT) [27,28]. On the contrary, in healthy
PBMCs, these drugs were not only poorly active, but they also
failed to show any cooperation (Figure S4). These data indicate
that inhibition of SIRT1 (and possibly of other sirtuins affected by
the concentrations of inhibitors tested) has per se limited cytotoxic
activity in leukemia cells. However, sirtuin inhibitors and HDAC
inhibitors potentiate each other’s activity.
To confirm the role of SIRT1 inhibition in the synergy between
sirtuin and HDAC inhibitors in leukemia cells we silenced this
sirtuin member in Jurkat cells by transfecting the cells in the
presence of a SIRT1-specific siRNA or a non-targeting siRNA as a
control (Figure S5A). Indeed, SIRT1 silencing increased HDAC
inhibitor-induced cell death (Figure S5B).
Finally, we sought to determine whether SIRT1 expression
would predict the efficacy of the combination sirtuin inhibitor/
HDAC inhibitor. To this end, we determined SIRT1 levels by
quantitative PCR (QPCR) in the primary leukemia samples and in
the leukemia cell lines used and compared these to SIRT1
expression in healthy PBMCs. Although with some variability
among samples, SIRT1 expression in primary leukemia cells (B-
CLL and AML) was found to be similar to that observed in healthy
leukocytes (Figure S6A). Conversely, in U937, Jurkat, and 697
cells, SIRT1 was expressed at lower levels as compared to PBMCs
(Figure S6B). Finally, in B-CLL cells, which represented the largest
available group of samples, no correlation between cytotoxic
activity or CI of the combination sirtuin inhibitor plus HDAC
inhibitor or Nampt inhibitor plus HDAC inhibitor (see below)
was observed (Figure S7, S8). Thus, SIRT1 levels as detected by
QPCR do not appear to be predictive of the activity of combined
sirtuin and HDAC inhibition.
Combined HDAC and sirtuin inhibitors trigger the
apoptotic cascade in leukemia cells
Cambinol alone and, to a higher degree, in combination with
VA, produced changes in Jurkat, 697 and U937 cells that are
typically observed during apoptosis, including: an increase in the
percentage of Annexin-V
+/PI
2 (early apoptotic) and Annexin-V
+/
PI
+ (late apoptotic) cells; the appearance of hypodiploid cell nuclei;
caspase-3 cleavage and a consistent increase in caspase-3/-7
enzymatic activity (Figure 2A–D and data not shown). To formally
assess the role of caspase activity in leukemia cell death in response
to the stimuli under investigation, we made use of the pan-caspase
inhibitor zVAD-fmk. Since the latter strongly reduced cell death
in response to sirtuin inhibitors and to their combination with
HDAC inhibitors (Figure 2E, F, Figure S9), we concluded that
these compounds kill leukemia cells via caspase-mediated apoptosis.
HDAC inhibitor-induced Bax upregulation is involved in
leukemia cells sensitization to sirtuin inhibitors
Apoptotic cell death can be initiated by different mechanisms
[29]. Irreversible damage of intracellular components usually
results in activation of the intrinsic mitochondrial apoptotic path-
way. Conversely, the surface death receptor pathway is normally
initiated by extracellular stimuli, although autocrine activation
mechanisms have also been proposed for this apoptotic route.
Using tetramethylrhodamine ethyl ester (TMRE) cell staining, we
found that cambinol induced mitochondrial transmembrane
potential (YDm) dissipation in leukemia cells, and that VA strongly
enhanced this effect, suggesting that the mitochondrial apoptotic
machinery is activated in response to these stimuli (Figure 3A and
data not shown). To gain insight into this phenomenon, we
focused on the pro-apoptotic Bcl-2 family member Bax, since this
protein plays a key role in mitochondrial permeability transition
pore formation and is also an established target of SIRT1’s
anti-apoptotic activity [10,30,31]. Namely, SIRT1 induces Bax
sequestration away from mitochondria by promoting its interac-
tion with Ku70 [30,31]. Moreover, Bax expression is known to be
down-regulated by HDACs and, accordingly, HDAC inhibitors
induce Bax upregulation [18,32,33,34]. Indeed, using flow
cytometry and western blotting we found increased Bax levels in
VA-treated Jurkat cells (Figure 3B, S10A). Similarly, VA increased
Bax amounts in U937 and 697 cells (Figure S10A). Conversely, in
healthy PBMCs, VA failed to induce Bax upregulation (Figure
S10B). Since previous experiments indicated that SIRT1 inhibi-
tion induces apoptosis in the presence of Bax overexpression,
we hypothesized that Bax accumulation mediated by HDAC
inhibitors, compounded by sirtuin inhibition, could be a vital
factor making leukemia cells especially susceptible to mitochon-
drial damage and subsequent apoptosis observed in response to
these drugs. To confirm that increased Bax levels would enhance
cell death via SIRT1 inhibition, we retrovirally engineered Jurkat
cells to overexpress Bax (Figure 3C). Indeed, Jurkat cells with
increased Bax levels were highly predisposed to cell demise upon
treatment with the sirtuin inhibitors EX527 and cambinol
(Figure 3D). Finally, to formally define Bax’s role in the cytotoxic
activity of sirtuin inhibitors and of their combination with HDAC
inhibitors, we silenced Bax in 697 and in U937 cells with a
validated anti-Bax shRNA (Figure 4A). Cells engineered to express
an anti-EGFP shRNA were used as a control. As predicted, in cells
with reduced Bax levels, cell death in response to sirtuin inhibitors
alone or in combination with VA was reduced (Figure 4B–D), thus
confirming the role of this pro-apoptotic protein in cell death in
response to these stimuli.
NAD
+-biosynthesis inhibition with FK866 synergistically
enhances HDAC inhibitor activity in leukemia cells
Sirtuins depend on NAD
+ for their enzymatic activity [3,4,21].
The Nampt inhibitor FK866 impairs sirtuin activity by reducing
intracellular NAD
+ availability, as shown by the observation that
SIRT1 targets are hyperacetylated in FK866-treated cells [35].
Since FK866 (as well as other Nampt inhibitors) has already
undergone preclinical and clinical studies [36,37], we aimed to
assess whether the same level of synergy observed with combined
sirtuin and HDAC inhibitors would be seen when replacing the
sirtuin inhibitors with FK866.
Treatment with FK866 effectively reduced intracellular NAD
+
concentration in leukemia cells, whereas the HDAC inhibitor VA
failed to diminish intracellular NAD
+ content (Figure S11A).
Moreover, as shown in Figure S11B, FK866-induced cell death
was reversed by supplementation with exogenous NAD
+, thus
confirming that the mode of action of this drug is related to NAD
+-
depletion. In primary AML cells, primary B-CLL cells, and in the
leukemia cell lines, FK866 enhanced the cytotoxic activity of the
HDAC inhibitors in a synergistic manner (Figure 5, 6A–B, S12,
S13, S14, S15, and Table S5). In Figure 6A, B, the CIs of the
combination FK866/VA in primary leukemia samples (AML and
B-CLL) are plotted vs. the specific cell deaths caused by this drug
combination. The raw viability data of these measurements as well
as the results obtained with the combination FK866/BU are
presented in Table S5. Noticeably, we found that the broad
spectrum HDAC inhibitor vorinostat also synergistically interacted
with FK866 in primary leukemia cells and in leukemia cell lines
(Figure S12, S13, S14, and data not shown) [1], thus confirming
the findings obtained with VA and BU. Finally, in healthy PBMCs
HDACs, Sirtuins, and Leukemia Cell Survival
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+ peripheral blood precursor cells (PBPCs), the
synergistic interaction between FK866 and the HDAC inhibitors
(VA or BU) was not observed (Figure 6C–E). Therefore, these
results are consistent with FK866 recreating the antileukemic
activity of sirtuin inhibitors and their capacity to potentiate HDAC
inhibitor-induced cell death in leukemia cells.
Discussion
Our data indicate that sirtuin and HDAC inhibitors cooperate
to the killing of human leukemia cells. A two-pronged mechanism
is shown to contribute to this form of synergy. On the one hand,
HDAC inhibitors upregulate the pro-apoptotic Bcl2-family protein
Bax. In turn, this condition predisposes leukemia cells to apoptotic
cell demise when SIRT1 is inhibited. These findings are in line
with previous studies which showed that SIRT1 prevents Bax-
mediated apoptosis by causing its cytoplasmic sequestration by
Ku70, and that SIRT1 blockade results in initiation of the intrinsic
apoptotic pathway in the presence of Bax overexpression [30,31].
We confirmed Bax’s role in the synergy between sirtuin and
HDAC inhibitors in leukemia cells by overexpressing it and by
showing that increased Bax amounts indeed augment the efficacy
of sirtuin inhibitors. Moreover, silencing Bax by stable RNA
interference was found to reduce the activity of sirtuin inhibitors
and of their combination with VA. However, it was of interest to
observe that, despite efficient Bax silencing, the activity of sirtuin
inhibitors, alone or coupled to VA, was not fully abolished. These
findings suggest that Bax-independent mechanisms may also play
a role in the antileukemic activity of these drugs. This is not
surprising given how broadly sirtuin- and HDAC-mediated
protein modifications are predicted to affect protein expression
and activity, resulting in increased predisposition to apoptotic
programs in malignant cells [1,2,10].
The Nampt inhibitor FK866 reduces SIRT1 activity by
diminishing intracellular NAD
+ levels [21]. Studies show that
FK866 has antileukemic activity in vitro and in leukemia and
lymphoma animal models [38,39]. Our experiments indicate that
indeed FK866 behaves similarly to sirtuin inhibitors in terms of
Figure 2. Combined HDAC and sirtuin inhibition synergistically induces apoptosis in leukemia cells. A–D 1610
6 Jurkat, 697, or U937
cells/well were plated in 6-well plates and treated for 48 h with our without 50 mM cambinol, 100 mg/ml VA, or their combination. Thereafter, cells
were harvested, washed, and used for Annexin-V/PI staining and flow cytometry (A), flow cytometric quantification of hypodiploid cell nuclei (B),
protein lysates preparation for caspase-3 and c-tubulin detection by immunoblotting (C, 697 cells), detection of caspase-3/7 enzymatic activity (D,
697 cells). E, F, Jurkat cells and 697 cells were plated in 96-well plates and pre-incubated for 1 h with 100 mM zVAD-fmk. Thereafter, 50 mM cambinol,
100 mg/ml VA, their combination, or 100 ng/ml TRAIL were added to the medium. Viability was assessed 48 h later by flow cytometry. A, C, one
representative experiment out of three is shown. B, D–F, results are means 6 SD of three separate experiments.
doi:10.1371/journal.pone.0022739.g002
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leukemia cells. Therefore, since Nampt inhibitors for clinical uses
are already available and have shown to be well tolerated [36,37],
these could in principle replace sirtuin inhibitors in combination
protocols with HDAC inhibitors. Importantly, since the concen-
trations of FK866, VA, BU, and vorinostat used in our
experiments are within the pharmacological range [8,36,40,41],
these drug combinations are predicted to also show activity in
patients.
Audrito and colleagues have recently reported that SIRT1
inhibition with nicotinamide has cytotoxic activity on B-CLL cells,
and that this effect requires the presence of wild type p53 [13].
Previous studies showed that SIRT1 deacetylates p53, thereby
preventing its transcriptional activity [16,17]. Thus, SIRT1
inhibition was proposed to upregulate several p53-dependent
pro-apoptotic factors in B-CLL cells, thereby promoting apoptosis.
In our case, functional p53 did not appear to be required for
the synergy between sirtuin inhibitors (or FK866) and HDAC
inhibitors, since this form of cooperation was also observed in
primary B-CLL cells with 17p deletion. Moreover, Jurkat cells,
which carry a mutant p53, were also highly susceptible to the
combination of sirtuin and HDAC inhibitors. Nonetheless, it
remains conceivable that, at least in some of the cases we studied,
increased p53-mediated transcription via SIRT1 inhibition did
contribute to the observed synergistic cytotoxicity.
It has to be noticed that, although we confirmed SIRT1’s role in
the synergy between sirtuin and HDAC inhibitors by RNAi-
mediated SIRT1 silencing, we cannot in principle exclude that
Figure 3. HDAC inhibitor-induced Bax upregulation contributes to the synergy with sirtuin inhibitors. A, 3610
6 primary AML cells/well
were plated in 6-well plates and incubated in the presence or absence of 50 mM cambinol, 100 mg/ml VA, or their combination. DYm was monitored
at the indicated time points by TMRE staining and flow cytometry. B, 1610
6 Jurkat cells were plated in 6-well plates and incubated for 48 h in the
presence or absence of 100 mg/ml VA. Thereafter, intracellular Bax content was determined by flow cytometry. C, D, Jurkat cells were transduced with
either pMIG or pMIG-Bax. Infected cells were FACS sorted, allowed to expand, and subsequently used for flow cytometric detection of intracellular
Bax (C) and for viability assays (D). For these, pMIG- or pMIG-Bax-transduced Jurkat were plated in 96-well plates and incubated in the presence or
absence of EX527 or cambinol at the indicated concentrations. Viability was determined by PI staining and flow cytometry 48 h later. A–C, one
representative experiment out of three is presented. D, Results are means 6 SD of three separate experiments.
doi:10.1371/journal.pone.0022739.g003
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synergy. As a matter of fact, the sirtuin inhibitors used in this study
are not specific for SIRT1 and can also inhibit other sirtuins,
including SIRT2, SIRT3, and, possibly, SIRT6 [10,24,25,26].
The same applies to the Nampt inhibitor FK866 [20,21,22,
23,24,25]. SIRT6 involvement in the synergy with HDAC
inhibitors is unlikely since Jurkat cells where SIRT6 had been
silenced by RNA-interference failed to exhibit increased suscep-
tibility to HDAC inhibitors (data not shown). We suggest that the
potential of other sirtuins as targets for treating leukemias is further
investigated.
Combined sirtuin and HDAC inhibitors (or FK866 and HDAC
inhibitors) showed antileukemic activity against cells of different
lineages (primary AML, primary B-CLL, U937, 697, and Jurkat
cells), suggesting that such drug combinations may find ap-
plications in a broad spectrum of hematological malignancies.
Interestingly, as opposite to what was observed in leukemia cells,
HDAC and sirtuin inhibitors were poorly active and failed to
show any cooperation in CD34
+ hematopoietic progenitors and
in PBMCs. For classical HDAC inhibitors, preferential activity
against malignant tissues has been reported [2,18]. The fact that
cancer cells frequently express higher amounts of certain HDACs,
and a peculiar composition of the HDAC complexes in malignant
cells have both been proposed as possible reasons for this
selectivity [2,18]. In contrast to Audrito and co-workers [13], we
failed to detect increased SIRT1 expression in B-CLL cells as
compared to healthy leukocytes. This could be due to the fact that
these authors compared B-CLL cells to healthy B cells, while in
our case SIRT1 expression in B-CLL cells was compared to its
levels in PBMCs (which are mostly CD3
+ T cells). However, as a
possible explanation for the preferential activity of combined
sirtuin and HDAC inhibitors in leukemias, we found that HDAC
inhibition increases Bax’s levels in leukemia cells, but not in
healthy leukocytes. Thus, it is likely that, by removing one arm of
the two-pronged mechanism that we found underlie this form of
synergy, the cooperation between the two types of agents is
disabled. Further studies should address the specificity of sirtuin
and HDAC inhibitors for leukemic cells. However, regardless of
the underlying mechanism, these data highlight a specific
requirement for sustained sirtuin and HDAC activity by leukemia
Figure 4. Bax silencing reduces sirtuin inhibitor activity in leukemia cells. A, B, U937 and 697 cells were transduced to either express an
anti-EGFP shRNA (EGFP-sh) or a validated anti-Bax shRNA (Bax-sh). Thereafter cells were used for cell lysate preparation and Bax and c-tubulin were
detected by immunoblotting. B, EGFP-sh or Bax-sh 697 cells were incubated with or without 100 mg/ml VA, 75 mM EX527, 50 mM cambinol, or their
combinations. Viability was assessed 36 h later by PI staining and flow cytometry. C, D, EGFP-sh or Bax-sh U937 cells were incubated with or without
100 mg/ml VA, 150 mM EX527, 100 mM cambinol, or their combinations. 36 h later, cells were imaged by light microscopy (D) and cell death was
determined by flow cytometric quantification of PI-positive cells (C). A, D, one representative experiment out of three is presented. B, C, Results are
means 6 SD of three separate experiments. *: p,0.05.
doi:10.1371/journal.pone.0022739.g004
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be exploited therapeutically.
In conclusion, sirtuin inhibitors(orFK866) and HDAC inhibitors
cooperate in turning off cellular mechanisms that protect leukemia
cells from apoptosis. Co-administration of sirtuin and HDAC
inhibitors should be further examined for clinical applications.
Materials and Methods
Ethics statement
The collection of peripheral blood samples from leukemia
patients and healthy volunteers for in vitro assays and drug testing
wasapproved by the EthicsCommittee of the SanMartino Hospital
(Genoa, Italy). Samples were collected following written informed
consent obtainment according to the Declaration of Helsinki.
Cell lines and reagents
U937, Jurkat, 293T, and Phoenix cells were obtained from
ATCC (LGC Standards, Teddington, UK). 697 cells were pur-
chased from German Collection of Microorganisms and Cell
Cultures (DSMZ, Braunschweig, Germany). Cells were grown in
RPMI 1640-based medium supplemented with 10% FBS and
antibiotics. Sirtinol, cambinol, VA, BU, NAD
+, and TMRE were
purchased from Sigma-Aldrich (Sigma Aldrich Italia, Milano,
Italy). EX527 was from Tocris Bioscience (Bristol, UK). Vorinostat
was from Selleck Chemicals LLC. zVAD-fmk was from Merck
Chemicals (Nottingham, UK). FK866 was generously provided by
the NIMH Chemical Synthesis and Drug Supply Program.
Primary cell isolation
Peripheral blood samples were obtained from healthy donors
(n=10) and patients with B-CLL (n=36) or AML (n=12) at the
Department of Internal Medicine of the University of Genoa,
Genoa, Italy. The clinical and laboratory features of the B-CLL
and AML patients are summarized in Table S6 and S7,
respectively. B-CLL cells were isolated by density gradient cen-
trifugation with Ficoll-Hypaque (Biotest, Dreieich, Germany). The
B-CLL phenotype of the obtained cell preparations was confirmed
by immunostaining with anti-CD19, anti-CD5, and anti-CD23
(Immunotech, Marseille, France), and subsequent flow cytometric
Figure 5. FK866 and HDAC inhibitors synergistically kill primary B-CLL cells. PrimaryB-CLLcellswereincubatedwithorwithoutFK866atthe
indicated concentrations for 48 h. Thereafter, VA or vorinostat were added at the indicated concentrations. Viability was assessed 48 h later by PI cell
staining and flow cytometry. CI values refer to the highest drug concentrations used. CI
CTs for each drug combination are presented in the lower insets.
doi:10.1371/journal.pone.0022739.g005
HDACs, Sirtuins, and Leukemia Cell Survival
PLoS ONE | www.plosone.org 7 July 2011 | Volume 6 | Issue 7 | e22739analysis. The purity of the isolated B-CLL cells was typically
.85%. AML blasts were isolated by adding a 6% dextran solution
(Fresenius Kabi, Varese, Italy) to the blood specimens at a ratio of
4:5, followed by 1-h incubation at room temperature. Thereafter,
the leukocytes-enriched supernatants were transferred to a 50 ml
conical centrifuge tube and centrifuged at 3006 g for 10 min.
Residual red blood cells were lysed by resuspending the cell pellets
in 4 ml 0.2% NaCl followed by addition of 4 ml 1.6% NaCl and
immediate centrifugation at 3006g for 10 min. Normal PBMCs
were isolated from healthy donor blood samples by density
gradient centrifugation with Ficoll-Hypaque. Cells were either
used immediately for viability assays, or stored at 280u in medium
containing 20% FBS and 10% DMSO. CD34
+ peripheral blood
precursor cells (PBPCs) were obtained from excess PBPC
concentrates (1–2 ml) from G-CSF-mobilized patients undergoing
autologous PBPC transplantation, following informed consent
according to the Declaration of Helsinki. CD34
+ cells were
purified using the CD34 MicroBead Kit from Miltenyi Biotec
(Bergisch Gladbach, Germany) following the manufacturer’s
instructions. Using this method, CD34
+ cells were typically
.80% pure and .80% viable as detected by PI staining and
flow cytometry.
Viability assays
2610
5 cells/well (primary B-CLL and AML cells, PBMCs,
PBPCs) or 5610
4 cells/well (U937, 697, Jurkat cells) were plated
in 96 well plates in a final volume of 200 ml in the presence or
absence of the indicated stimuli. Dead cells were quantified at the
indicated times by PI staining (2 mg/ml) and flow cytometry
(FACS Calibur, Becton Dickinson, BD Italia, Milan, Italy). Spe-
cific death was calculated as follows: [(% experimental death2%
spontaneous death)/(1002% spontaneous death)]6100. FITC-
Annexin-V-PI staining was done with the Annexin-V-FITC Kit
from BioVision (Mountain View, CA, USA) according to the
manufacturer’s instructions. For the detection of hypodiploid cell
nuclei, cell pellets were resuspended in a buffer containing 0.1%
sodium citrate, 0.1% Triton-X 100, and 50 mg/ml PI. Thereafter,
cells were analyzed by flow cytometry.
DYm determination
Cells were harvested, washed, and incubated in the presence of
50 nM TMRE in regular RPMI-based medium for 15 min at
37uC. Thereafter, cells were analyzed by flow cytometry.
Immunoblotting
Cell lysates were generated from 1.5610
6 cells by directly
resuspending cell pellets in sodium dodecyl sulfate (SDS) sample
buffer (Tris-HCl 0.25 M, pH 6.8, SDS 2%, glycerol 10%, b-
mercaptoethanol 2%, bromophenol blue 0.005%; Boston Bio-
products, Boston, MA). Cell lysates were immediately boiled at
100uC for 10 minutes and stored at 220uC for subsequent use.
Proteins were separated on an SDS-polyacrylamide gel and
Figure 6. FK866/HDAC inhibitor synergistic interaction spares healthy leukocytes and CD34
+ PBPCs. A, B, Primary B-CLL or AML cells
were incubated with or without 10 nM FK866 for 48 h. Thereafter, 100 mg/ml VA was added (or not) to the medium. 48 h later, dead cells were
quantified by PI-staining and flow-cytometry. CIs for the combination FK866/VA were calculated and plotted vs. the specific cell death induced by the
same drug combination in each sample. C, D, Healthy PBMCs were incubated with or without FK866 at the indicated concentrations for 48 h.
Thereafter, VA or BU were added at the indicated concentrations. Viability was assessed 48 h later by PI cell staining and flow cytometry. CI values
refer to the highest drug concentrations used. E, Healthy CD34
+ PBPCs were incubated in 96-well plates and treated with 10 nM FK866 for 48 h.
Subsequently, 100 mg/ml VA or 500 mM BU were added where indicated. Viability was assessed 48 h later. CI values for the drug combinations are
indicated inside the graph area. C–E, Results are means of three separate experiments with three different donors.
doi:10.1371/journal.pone.0022739.g006
HDACs, Sirtuins, and Leukemia Cell Survival
PLoS ONE | www.plosone.org 8 July 2011 | Volume 6 | Issue 7 | e22739electroblotted to a polyvinylidene difluoride (PVDF) mem-
brane (Pall Gelman Laboratory, Ann Arbor, MI). Proteins were
visualized by probing the membranes with the following anti-
bodies: anti-caspase-3, anti-SIRT1 (Cell Signaling Technology),
anti-Bax, (rabbit polyclonal, Santa Cruz Biotechnology), and anti-
c tubulin (mouse monoclonal, Sigma Aldrich).
Caspase activity assays
Caspase activity was determined with the Apo-ONE Caspase-3/
7 Kit from Promega according to the manufacturer’s instructions.
Immunostaining and flow cytometric detection of
intracellular Bax
For intracellular detection of Bax levels, cells were fixed in 2%
paraformaldehyde for 10 min at room temperature. Cells were
subsequently washed and permeabilized using 0.5% Triton X-100
in PBS for 5 min at room temperature. Thereafter, cells were
washed and incubated with rabbit anti-human Bax polyclonal
antibody (BD Biosciences, USA) for 30 min at 4uC according to
the manufacturer’s instructions. Thereafter, cells were washed and
incubated with a FITC-conjugated rabbit anti-mouse antibody (a
kind gift of Dr. Alessandro Poggi, National Cancer Institute,
Genoa, Italy) for 30 min at 4uC. Finally, cells were analyzed by
flow cytometry.
Retroviral transduction
Phoenix cells were plated in 4 ml medium in 6 cm-dishes and
allowed to adhere for 24 h. Thereafter, cells were transfected with
4 mg plasmid DNA (pMIG, Dr. William Hahn, Dana Farber
Cancer Institute, Boston, MA, USA; or pMIG-Bax, Dr. Stanley J.
Korsmeyer, Dana Farber Cancer Institute, Boston, MA, US, both
from Addgene, Cambridge MA, USA) using Transit 293 (Mirus
Bio, Madison, WI, USA). The viral supernatant was harvested 36
and 48 h later and used to infect Jurkat cells in 24-well plates in
the presence of 5 mg/ml protamine sulfate. pMIG- and pMIG-
Bax-infected Jurkat cells were FACS-sorted for EGFP expression
using a FACSAria Cell Sorter (Becton Dickinson, BD Italia).
For lentivirus-mediated shRNA delivery, 293T cells were used
as a packaging cell line. 7610
5 cells were plated in 4 ml medium in
6 cm-dishes, allowed to adhere for 24 h, and subsequently
transfected with 2 mg MISSION EGFP shRNA Control Vector
(Sigma Aldrich; pLKO.1 variant; short hairpin sequence 59-
CCGGTACAACAGCCACAACGTCTATCTCGAGATGGTT-
CTGATCAGTTCCGGCTTTTTG-39) or MISSION Bax shRNA
Vector (Sigma Aldrich; pLKO.1 variant; short hairpin sequence 59-
CCGGGCCGGAACTGATCAGAACCATCTCGAGATGGTT-
CTGATCAGTTCCGGCTTTTTG-39), 0.7 mg VSVG-, 0.7 mg
gag/pol-, and 0.7 mg env-encoding plasmids using Transit 293. The
viral supernatant was harvested 36 and 72 h later and used to infect
U937 and 697 cells in 24-well plates in the presence of 5 mg/ml
protamine sulfate. Infected cells were selected using 1 mg/ml
puromycin.
siRNA transfection
Jurkat cells were transfected using the Nucleofector System
(Amaxa GmbH, Cologne, Germany), with StealthTM duplex
short interference RNAs (siRNA) targeting SIRT1, or scrambled
siRNA (StealthTM Negative Control), all from Dharmacon
(Lafayette, CO).
Determination of intracellular NAD
+ levels
To determine intracellular NAD
+ content, 2610
6 cells, treated
or not, were harvested and lysed with 0.6 M perchloric acid
(PCA). Acid extracts were neutralized and the intracellular content
of NAD
+ was assessed with a sensitive enzymatic cycling assay
[42]. NAD
+ value was normalized to protein concentration
(Bradford assay, Bio-Rad Laboratories).
Q-PCR
Total RNA was extracted from 5610
5 cells using RNeasy kit
reagents (Qiagen, Qiagen Italia, Milan, Italy). Total RNA (1 mg)
was reverse transcribed using random hexamers in a final volume
of 50 ml. 5 ml of the resulting cDNA was used for Q-PCR using a
TaqMan 7900 HT Fast Real TimeAB. Pre-designed primers
and probes for SIRT1, and RPLP0 were obtained from Applied
Biosystems. Gene expression was normalized to housekeeping
gene expression (RPLP0). Comparisons in gene expression were
done using the 2
2DDCt method.
Light Microscopy
Cells were imaged at room temperature using with the 206
magnification of a Zeiss AXIOVERT200 microscope, an Olym-
pus C-4040ZOOM camera, and the software Olympus CAME-
DIA Master 2.5.
Statistical analysis
Each experiment was performed at least three times. The
cooperative index (CI) was calculated as the sum of the specific cell
deaths induced by the single agents divided by the specific cell
death in response to the combination. CI values ,1, =1 and .1
indicate a synergistic, additive or infra-additive effect respectively
[27]. The Combination Index according to Chou and Talalay
(CI
CT) was calculated with Calcusyn Version 2.1 software (Biosoft,
Cambridge, UK): CI
CT=C 1,x/ICx,1+C2,x/ICx,2.C 1,x and C2,x are
the concentrations of the first and of the second compound,
respectively, which achieve x% drug effect when the compounds
are used in combination [28]. ICx,1 and ICx,2 are the single agent
concentrations required for the same effect. A CI
CT,1 is con-
sidered indicative of a synergistic drug interaction. GraphPad
Prism version 4.00 (GraphPad Software, San Diego,CA) was
used for the t-tests and to calculate the Pearson correlation
coefficients.
Supporting Information
Figure S1 EX527 and VA synergistically kill primary B-
CLL cells. Primary B-CLL cells were plated in 96-well plates and
incubated with or without EX527 and VA at the indicated
concentrations. Viability was assessed 48 h later by PI cell staining
and flow cytometry. The CI value refers to the highest drug
concentrations used.
(PDF)
Figure S2 EX527 and VA cooperate in 697 cells. 697 cells
were incubated with or without EX527 or VA at the indicated
concentrations. Viability was assessed 48 h later by PI cell staining
and flow cytometry. CI values refer to the highest drug con-
centrations used. The CI
CTs for the different drug combinations
are presented in the lower insets.
(PDF)
Figure S3 Sirtuin inhibitors and HDAC inhibitors
synergistically kill Jurkat cells. A–D, Jurkat cells were
incubated in 96-well plates with or without EX527, cambinol, BU,
or VA at the indicated concentrations. Viability was assessed 48 h
later by PI cell staining and flow cytometry. CI values refer to the
highest drug concentrations used.
(PDF)
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poor activity and fail to cooperate in healthy PBMCs. A–
C, Healthy PMBCs were incubated in 96-well plates with or
without sirtinol, cambinol, BU, or VA at the indicated con-
centrations. Viability was assessed 48 h later by PI cell staining
and flow cytometry. CI values refer to the highest drug con-
centrations used. Results are means 6 SD of three independent
experiments with three different donors.
(PDF)
Figure S5 SIRT1 silencing enhances HDAC inhibitor
activity in Jurkat cells. A, B. Jurkat cells were transfected
with a non-targeting siRNA (cntr siRNA) or with an anti-SIRT1-
siRNA. Thereafter, two days later, cells were used for protein
lysate preparation or plated in 96-well plates for viability assays. A,
SIRT1 and c-tubulin levels were determined by immunoblotting.
B, Cells were incubated in the presence or absence of the indicated
concentrations of VA or of BU. Two days later, dead cells were
quantified by PI staining and flow cytometry. One representative
experiment out of three is presented. *: p,0.05.
(PDF)
Figure S6 SIRT1 expression in primary leukemia cells
and in leukemia cell lines. A, RNA was extracted from freshly
isolated normal PBMCs (n=10), primary B-CLL cells (n=36),
AML cells (n=11), and from the cell lines U937, Jurkat, and 697.
SIRT1 levels were determined by Q-PCR. SIRT1 levels in
primary leukemia samples (A) and in cell lines (B) were compared
to the mean value obtained in PBMCs using the 2
2DDCT method.
(PDF)
Figure S7 Correlation between SIRT1 expression and
activity of the combination sirtuin/HDAC inhibitors in
leukemia cells. Primary B-CLL cells were plated in 96
well plates and treated with or without 100 mg/ml VA, 500 mM
BU, 50 mM cambinol, or their combinations. Dead cells were
enumerated two days later by PI staining and flow cytometry. The
correlation between the CI (A, B) or the overall cytotoxic activity
(C, D) of each drug combination and SIRT1 expression was
assessed by Pearson correlation coefficient.
(PDF)
Figure S8 Correlation between SIRT1 expression and
activity of the combination FK866/HDAC inhibitors in
leukemia cells. Primary B-CLL cells were treated with or
without 10 nM FK866, 100 mg/ml VA, 500 mM BU, or their
combination. Dead cells were enumerated four days later by PI
staining and flow cytometry. The correlation between the CI (A,
B) or the overall cytotoxic activity (C, D) of each drug combination
and SIRT1 expression was assessed by Pearson correlation
coefficient.
(PDF)
Figure S9 zVAD-fmk reduces cell death in response to
sirtuin and HDAC inhibitors in leukemia cells. A, Jurkat
cells were pre-incubated for 1 h with or without 100 mM zVAD-
fmk. Thereafter, 100 mg/ml VA, 30 mM sirtinol, 75 mM EX527,
or their combinations were added as indicated. Viability was
assessed two days later by PI staining and flow cytometry. B–D,
697 cells were pre-incubated for 1 h with or without 100 mM
zVAD-fmk. Thereafter, 100 mg/ml VA, 30 mM sirtinol, or their
combination were added as indicated. Two days later, cells were
imaged by light microscopy (D), dead cells were enumerated by
PI staining and flow cytometry (B), and hypodiploid cell nuclei
were counted by PI staining of isolated cell nuclei and flow
cytometry (C).
(PDF)
Figure S10 VA induces Bax upregulation in leukemia
cell lines, but not in healthy PBMCs. A, 3610
6 Jurkat,
U937, and 697 cells were plated in 6-well plates in the presence or
absence of 100 mg/ml VA. Two days later, cells were harvested,
washed and used for protein lysate preparation. Bax and c-tubulin
levels were determined by immunoblotting. B, 10
7 PBMCs were
plates in 3 ml medium in 6-well plates in the presence or absence
of the indicated concentrations of VA. Two days later, cells were
harvested, washed, and used for cell lysate preparation. Bax and c-
tubulin expression were determined by immunoblotting. A, B one
representative experiment out of three is shown.
(PDF)
Figure S11 FK866-mediated NAD
+ depletion mediates
FK866’s cytotoxic activity. A, Primary B-CLL and AML cells
were incubated in 24-well plates in the presence or absence of
10 nM FK866, 100 mg/ml VA, 500 mM BU, or their combina-
tion. 48 h later, NAD
+ levels were determined by enzymatic
cycling assay. NAD
+ values were normalized to protein content
(expressed in mg). B, Primary AML cells were plated in 96-well
plates and incubated with 100 nM FK866. NAD
+ was added to
the medium every 12 h in order to achieve the indicated
concentrations. Viability was quantified after 96 h of incubation
by PI staining and flow-cytometry.
(PDF)
Figure S12 FK866 and HDAC inhibitors synergistically
kill primary B-CLL cells. Primary B-CLL cells were incubated
with or without FK866 at the indicated concentrations for 48 h.
Thereafter, VA or vorinostat were added at the indicated con-
centrations. Viability was assessed 48 h later by PI cell staining
and flow cytometry. CI values refer to the highest drug con-
centrations used. CI
CTs for each drug combination are presented
in the lower insets.
(PDF)
Figure S13 Synergistic interaction between FK866 and
HDAC inhibitors in the AML cell line U937. U937 cells
were incubated with or without FK866 at the indicated con-
centrations for 48 h. Thereafter, VA, vorinostat, or BU were
added at the indicated concentrations. Viability was assessed 48 h
later by PI cell staining and flow cytometry. CI values refer to the
highest drug concentrations used. CI
CTs for each drug combina-
tion are shown in the lower insets.
(PDF)
Figure S14 Synergistic interaction between FK866 and
HDAC inhibitors in Jurkat cells. Jurkat cells were incubated
with or without FK866 at the indicated concentrations for 48 h.
Thereafter, VA, vorinostat, or BU were added at the indicated
concentrations. Viability was assessed 48 h later by PI cell staining
and flow cytometry. CI values refer to the highest drug con-
centrations used. CI
CTs for each drug combination are presented
in the lower insets.
(PDF)
Figure S15 Synergistic interaction between FK866 and
VA in 697 pre-B-cell leukemia cells. 697 cells were incubated
with or without FK866 at the indicated concentrations for 48 h.
Thereafter, VA was added at the indicated concentrations.
Viability was assessed 48 h later by PI cell staining and flow
cytometry. CI values refer to the highest drug concentrations used.
CI
CTs are shown in the lower inset.
(PDF)
Table S1 Synergistic interactions between cambinol
and VA in primary leukemia cells. Primary B-CLL (#3,
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#46) cells were plated in 96 well plates and stimulated with
100 mg/ml VA, cambinol (camb.) at the indicated concentrations,
or their combinations. Specific cell death was detected four days
later by flow cytometry. CIs are indicated in parenthesis. ND: not
determined.
(PDF)
Table S2 Synergistic interactions between cambinol
and BU in primary leukemia cells. Primary B-CLL cells
were plated in 96 well plates and stimulated with 500 mM BU,
cambinol (camb.) at the indicated concentrations, or their
combinations. Specific cell death was detected four days later by
flow cytometry. CIs are indicated in parenthesis.
(PDF)
Table S3 Synergistic interactions between sirtinol and
VA in primary leukemia cells. Primary B-CLL (#3, #9,
#11, #12, #13, #19, #24, #27, #33, #36) or AML (#41, #42,
#46) cells were plated in 96 well plates and stimulated with
100 mg/ml VA, sirtinol (sirt.) at the indicated concentrations, or
their combinations. Specific cell death was detected four days later
by flow cytometry. CIs are indicated in parenthesis.
(PDF)
Table S4 Synergistic interactions between sirtinol and
BU in primary leukemia cells. Primary B-CLL (#3, #9,
#11, #12, #13, #19, #24, #27, #33) or AML (#41, #42) cells
were plated in 96 well plates and stimulated with 500 mM BU,
sirtinol (sirt.) at the indicated concentrations, or their combina-
tions. Specific cell death was detected four days later by flow
cytometry. CIs are indicated in parenthesis.
(PDF)
Table S5 Synergistic interactions between FK866 and
HDAC inhibitors in primary leukemia cells. Primary B-
CLL (#1–35) or AML (#37–45) cells were plated in 96 well plates
and stimulated with 100 mg/ml VA, 500 mM BU, 10 nM FK866
or their combinations. Specific cell death was detected four days
later by PI staining and flow cytometry. CIs are indicated in
parenthesis. ND: not determined.
(PDF)
Table S6 Clinical and laboratory features of patients
with B-CLL. ND: not determined; Nor, normal; +: trisomy;
*:chemonaive patient.
(PDF)
Table S7 Clinical and laboratory features of patients
with AML. PB: peripheral blood.
(PDF)
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